M
M.J. Chapman
Researcher at French Institute of Health and Medical Research
Publications - 10
Citations - 797
M.J. Chapman is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Lipoprotein & Density gradient ultracentrifugation. The author has an hindex of 9, co-authored 10 publications receiving 785 citations.
Papers
More filters
Journal ArticleDOI
Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor
TL;DR: The interaction of individual LDL subspecies with the LDL receptor on cultured human U-937 monocyte-like cells was compared by determining receptor binding affinities at 4 degrees C and scatchard analysis of specific binding curves demonstrated a single class of binding site for each subspecies.
Journal ArticleDOI
Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.
TL;DR: It is suggested that in consequence of their elevated circulating concentration and diminished oxidative resistance, dense LDL subspecies represent putative atherogenic subspecies in combined hyperlipidemia.
Journal ArticleDOI
Plasma lipoproteins in the golden Syrian hamster (Mesocricetus auratus): heterogeneity of apoB- and apoA-I-containing particles.
Sylvie Goulinet,M.J. Chapman +1 more
TL;DR: The core lipid contents of apoB- and apoA-I-containing lipoproteins are consistent with the hypothesis that the hamster is partially deficient in neutral lipid (CE, TG) transfer activity.
Journal ArticleDOI
Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP.
TL;DR: It is demonstrated that hsC-reactive protein is significantly negatively correlated with free thyroxine levels in non-smoker hyperlipidemic patients, suggesting that low thyroxines levels in euthyroid hyper Lipidemic subjects constitute a new biomarker of elevated cardiovascular risk.
Journal ArticleDOI
Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies
TL;DR: neutral effects of pitavastatin on glucose homeostasis were observed in two cohorts of patients with metabolic syndrome, independent of its efficacy in reducing levels of atherogenic lipoproteins, suggesting that statin-induced diabetogenesis may not represent a class effect.